Depakene and Tracleer drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Depakene and Tracleer. Common interactions include oesophageal carcinoma among females and sudden death among males.

The phase IV clinical study analyzes what interactions people who take Depakene and Tracleer have. It is created by eHealthMe based on reports of 11 people who take Depakene and Tracleer from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Sep, 22, 2022

11 people who take Depakene and Tracleer together, and have interactions are studied.


What is Depakene?

Depakene has active ingredients of valproic acid. It is often used in epilepsy. eHealthMe is studying from 14,609 Depakene users for its effectiveness, alternative drugs and more.

What is Tracleer?

Tracleer has active ingredients of bosentan. It is often used in primary pulmonary hypertension. eHealthMe is studying from 54,408 Tracleer users for its effectiveness, alternative drugs and more.

Number of Depakene and Tracleer reports submitted per year:

Depakene and Tracleer drug interactions.

Common Depakene and Tracleer drug interactions by gender *:

female:

  1. Oesophageal carcinoma
  2. Respiratory tract infection
  3. Splenomegaly
  4. Swelling
  5. Uterine enlargement
  6. Calculus urinary
  7. Cerebral infarction
  8. Pneumonia
  9. Cerebrovascular accident
  10. Death

male:

  1. Sudden death

Common Depakene and Tracleer drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Cardiogenic shock
  2. Clonic convulsion
  3. Duodenal ulcer haemorrhage
  4. Dyspnoea
  5. Eating disorder
  6. Gastrointestinal hypomotility
  7. Hepatitis
  8. Hepatomegaly
  9. Hypertension
  10. Ileus paralytic

30-39:

n/a

40-49:

  1. Cerebrovascular accident
  2. Loss of consciousness

50-59:

  1. Sudden death

60+:

  1. Oesophageal carcinoma
  2. Calculus urinary
  3. Cerebral infarction
  4. Pneumonia
  5. Death

Common conditions people have *:

  1. Pulmonary Hypertension (increase in blood pressure in the lung artery): 5 people, 45.45%
  2. Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 2 people, 18.18%
  3. Skin Ulcer: 2 people, 18.18%
  4. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 18.18%
  5. Stable Angina (a constant chest pain): 1 person, 9.09%
  6. Pain: 1 person, 9.09%
  7. Neuralgia (pain in one or more nerves): 1 person, 9.09%
  8. Insomnia (sleeplessness): 1 person, 9.09%
  9. High Blood Pressure: 1 person, 9.09%
  10. Stress And Anxiety: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Depakene and Tracleer?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Depakene and Tracleer:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Depakene interactions:

Browse all interactions between Depakene and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Tracleer interactions:

Browse all interactions between Tracleer and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on valproic acid and bosentan (the active ingredients of Depakene and Tracleer, respectively), and Depakene and Tracleer (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Depakene and Tracleer.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: